Wockhardt Ltd
Ravi Limaye OBE is an accomplished executive with extensive experience in the pharmaceuticals and healthcare sectors. Currently serving as the CEO of Wockhardt UK since January 2019, Ravi has previously held senior roles such as Advisor for Pharmaceuticals & Healthcare at Actis and President of the Global Commercial Organization at Biocon. Ravi's career also includes significant positions at Novartis as Senior Vice President overseeing specialty businesses and at GSK, where responsibilities ranged from leading the Established Products Unit for Emerging Markets to various strategic roles in sales, marketing, and business development. Educational qualifications include an M Pharm and an MBA from Bombay College of Pharmacy, Jamnalal Bajaj, and INSEAD.
This person is not in any teams
This person is not in any offices
Wockhardt Ltd
1 followers
Wockhardt Limited is a pharmaceutical and biotechnology company. The Company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines. Its products include Ace Proxyvon, Bio-Corneum, Aceroc, Alphadopa, Biovac Typhoid, Acetic Acid Otic Solution, Amlodipine Besylate Tablets, Adenosine Injection, Amoxicillin and Clavulanate Potassium for Oral Suspension, Azithromycin Tablets, Aciclovir Powder for Injection, Alendronic Acid, Amitriptyline, Clarithromycin, Entacapone Tablet and Flucloxacillin Injection. It operates a chain of approximately 10 super specialty hospitals, which offer treatment and care facilities in cardiology, neurosurgery, orthopedics, critical care, oncology, nephrology, urology and others. It has over 10 manufacturing plants located in India, the United Kingdom, Ireland and the United States. The Company has approximately three research centers globally.